MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$62M

Net Income

-$62M

EPS (Diluted)

$-3.72

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$47M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$328M

Total Liabilities

$57M

Stockholders' Equity

$271M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$62M	-$50M	-22.7%
Net Income	-$62M	-$49M	-25.8%

MDGL Q2 2021 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena